445 related articles for article (PubMed ID: 25780857)
1. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
3. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
4. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
5. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
7. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
[TBL] [Abstract][Full Text] [Related]
8. The Lesson Learned from the New c.2547-1G > T Mutation Combined with p.R854Q: When a Type 2N Mutation Reveals a Quantitative von Willebrand Factor Defect.
Casonato A; Cozzi MR; Ferrari S; Rubin B; Gianesello L; De Marco L; Daidone V
Thromb Haemost; 2022 Sep; 122(9):1479-1485. PubMed ID: 35189660
[TBL] [Abstract][Full Text] [Related]
9. Type 2N von Willebrand disease: Characterization and diagnostic difficulties.
Casonato A; Galletta E; Sarolo L; Daidone V
Haemophilia; 2018 Jan; 24(1):134-140. PubMed ID: 29115006
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand disease type 2N: An update.
Seidizadeh O; Peyvandi F; Mannucci PM
J Thromb Haemost; 2021 Apr; 19(4):909-916. PubMed ID: 33497541
[TBL] [Abstract][Full Text] [Related]
11. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
12. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.
Schneppenheim R; Lenk H; Obser T; Oldenburg J; Oyen F; Schneppenheim S; Schwaab R; Will K; Budde U
Thromb Haemost; 2004 Jul; 92(1):36-41. PubMed ID: 15213842
[TBL] [Abstract][Full Text] [Related]
13. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
14. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project.
Pérez-Rodríguez A; Batlle J; Pinto JC; Corrales I; Borràs N; Garcia-Martínez I; Cid AR; Bonanad S; Parra R; Mingot-Castellano ME; Navarro N; Altisent C; Pérez-Montes R; Moretó A; Herrero S; Soto I; Mosteirín NF; Jiménez-Yuste V; Jacob AA; Fontanes E; Mateo J; Quismondo NC; Batlle F; Vidal F; López-Fernández MF;
Haemophilia; 2021 Nov; 27(6):1007-1021. PubMed ID: 34494337
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
[TBL] [Abstract][Full Text] [Related]
16. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype.
van Meegeren ME; Mancini TL; Schoormans SC; van Haren BJ; van Duren C; Diekstra A; Laros-van Gorkom BA; Brons PP; Simons A; Hoefsloot L; van Heerde WL
Haemophilia; 2015 Sep; 21(5):e375-83. PubMed ID: 26207643
[TBL] [Abstract][Full Text] [Related]
18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
19. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]